Share Price and Basic Stock Data
Last Updated: January 1, 2026, 1:13 pm
| PEG Ratio | 5.98 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Granules India Ltd operates in the pharmaceutical sector, focusing on the manufacturing of active pharmaceutical ingredients (APIs) and finished dosages. The company reported a revenue of ₹4,512 Cr for the fiscal year ending March 2023, which showed a slight decline to ₹4,506 Cr in the following fiscal year. However, the trailing twelve months (TTM) revenue rose to ₹4,842 Cr, indicating positive momentum. Quarterly sales figures reveal fluctuations, with a peak of ₹1,196 Cr in March 2023 and a low of ₹986 Cr in June 2023, followed by a recovery to ₹1,189 Cr in September 2023. The company’s operational focus on cost management is evident as it reported sales growth despite a challenging operating environment. The revenue per share stood at ₹184.78 as of March 2025, reflecting a consistent operational scale. Overall, Granules India Ltd has shown resilience in maintaining revenue levels, even amidst market volatility.
Profitability and Efficiency Metrics
Granules India Ltd’s profitability metrics indicate a mixed performance. The operating profit margin (OPM) stood at 20% for the latest fiscal year, with an operating profit of ₹858 Cr reported for March 2024. While this represents a slight decline from the previous year’s OPM of 20%, it remains competitive within the sector. The net profit margin improved to 11.19% in March 2025 from 10.96% in March 2024, reflecting effective cost management strategies. Return on equity (ROE) was reported at 13.9%, and return on capital employed (ROCE) at 15.1%, suggesting efficient utilization of shareholders’ funds and capital. The interest coverage ratio (ICR) further emphasizes the company’s ability to manage debt, reported at 9.28x, indicating strong operational cash flow relative to its interest obligations. Despite some fluctuations, Granules India has maintained robust profitability metrics, showcasing its ability to navigate financial challenges effectively.
Balance Sheet Strength and Financial Ratios
Granules India Ltd’s balance sheet reflects a stable financial position, with total assets reported at ₹6,221 Cr as of March 2025. The company has maintained reserves of ₹3,959 Cr, indicating a strong buffer against market volatility. Total borrowings stood at ₹1,807 Cr, resulting in a manageable debt-to-equity ratio of 0.34x, suggesting low financial leverage compared to industry standards. The current ratio is reported at 1.56x, which exceeds the typical threshold of 1, indicating adequate liquidity to meet short-term obligations. The interest coverage ratio, at 9.28x, further enhances the company’s financial robustness, allowing it to comfortably cover interest expenses. However, the cash conversion cycle has lengthened to 207 days, raising concerns about working capital efficiency. Overall, Granules India Ltd’s balance sheet is characterized by solid reserves and manageable debt levels, although the elongated cash conversion cycle warrants monitoring.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Granules India Ltd reveals a diverse ownership structure. As of September 2025, promoters hold 38.81% of the shares, indicating a significant commitment to the company’s growth. Foreign institutional investors (FIIs) have reduced their stake to 14.09% from a high of 23.66% in December 2022, reflecting a cautious stance amid market fluctuations. Domestic institutional investors (DIIs) have increased their stake to 17.91%, signaling growing confidence from local institutions. The public’s shareholding remains substantial at 29.17%, with the total number of shareholders recorded at 165,542. The declining FII interest might pose a risk to stock liquidity, while the stable DII presence could provide a buffer against market volatility. Overall, the shareholding pattern indicates a mix of confidence and caution among different investor segments, reflecting a balanced investment outlook.
Outlook, Risks, and Final Insight
Granules India Ltd faces both opportunities and challenges in the evolving pharmaceutical landscape. The company’s strong revenue generation and profitability metrics suggest a solid operational foundation. However, the elongated cash conversion cycle and declining FII interest pose potential risks to liquidity and investor sentiment. The management’s ability to address these challenges while leveraging its operational strengths will be crucial for future growth. Furthermore, potential regulatory changes and competitive pressures within the pharmaceutical sector could impact performance. If Granules India can enhance its working capital efficiency and maintain investor confidence, it may capitalize on growth opportunities in the expanding market. Conversely, failure to address these risks could hinder its financial performance and stock price stability. The company’s ongoing strategic initiatives will play a pivotal role in navigating this complex landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 231/84.3 | 28.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,816 Cr. | 442 | 479/192 | 99.7 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.3 Cr. | 43.5 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 52.4 Cr. | 35.8 | 36.4/17.0 | 125 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,150.14 Cr | 1,152.36 | 53.49 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,020 | 1,151 | 1,146 | 1,196 | 986 | 1,189 | 1,156 | 1,176 | 1,180 | 967 | 1,138 | 1,197 | 1,210 |
| Expenses | 808 | 908 | 915 | 967 | 849 | 977 | 905 | 920 | 921 | 763 | 907 | 945 | 963 |
| Operating Profit | 212 | 243 | 231 | 228 | 137 | 213 | 250 | 256 | 259 | 203 | 230 | 252 | 247 |
| OPM % | 21% | 21% | 20% | 19% | 14% | 18% | 22% | 22% | 22% | 21% | 20% | 21% | 20% |
| Other Income | 5 | 5 | 1 | 3 | 0 | 2 | 1 | 2 | 2 | 3 | 6 | 33 | -10 |
| Interest | 7 | 13 | 17 | 19 | 22 | 26 | 29 | 29 | 27 | 26 | 27 | 24 | 24 |
| Depreciation | 43 | 44 | 48 | 49 | 49 | 53 | 52 | 53 | 53 | 53 | 57 | 64 | 69 |
| Profit before tax | 166 | 190 | 167 | 164 | 65 | 136 | 170 | 176 | 181 | 128 | 153 | 198 | 145 |
| Tax % | 23% | 24% | 26% | 27% | 27% | 25% | 26% | 26% | 26% | 24% | 23% | 23% | 22% |
| Net Profit | 128 | 145 | 124 | 120 | 48 | 102 | 126 | 130 | 135 | 97 | 118 | 152 | 113 |
| EPS in Rs | 5.14 | 5.84 | 5.14 | 4.94 | 1.98 | 4.21 | 5.18 | 5.35 | 5.56 | 4.01 | 4.85 | 6.27 | 4.64 |
Last Updated: August 20, 2025, 10:10 am
Below is a detailed analysis of the quarterly data for Granules India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,210.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,197.00 Cr. (Mar 2025) to 1,210.00 Cr., marking an increase of 13.00 Cr..
- For Expenses, as of Jun 2025, the value is 963.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 945.00 Cr. (Mar 2025) to 963.00 Cr., marking an increase of 18.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 247.00 Cr.. The value appears to be declining and may need further review. It has decreased from 252.00 Cr. (Mar 2025) to 247.00 Cr., marking a decrease of 5.00 Cr..
- For OPM %, as of Jun 2025, the value is 20.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Mar 2025) to 20.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is -10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to -10.00 Cr., marking a decrease of 43.00 Cr..
- For Interest, as of Jun 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Depreciation, as of Jun 2025, the value is 69.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 64.00 Cr. (Mar 2025) to 69.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 145.00 Cr.. The value appears to be declining and may need further review. It has decreased from 198.00 Cr. (Mar 2025) to 145.00 Cr., marking a decrease of 53.00 Cr..
- For Tax %, as of Jun 2025, the value is 22.00%. The value appears to be improving (decreasing) as expected. It has decreased from 23.00% (Mar 2025) to 22.00%, marking a decrease of 1.00%.
- For Net Profit, as of Jun 2025, the value is 113.00 Cr.. The value appears to be declining and may need further review. It has decreased from 152.00 Cr. (Mar 2025) to 113.00 Cr., marking a decrease of 39.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.64. The value appears to be declining and may need further review. It has decreased from 6.27 (Mar 2025) to 4.64, marking a decrease of 1.63.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:18 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,084 | 1,292 | 1,357 | 1,411 | 1,685 | 2,279 | 2,599 | 3,238 | 3,765 | 4,512 | 4,506 | 4,482 | 4,842 |
| Expenses | 925 | 1,082 | 1,081 | 1,112 | 1,406 | 1,895 | 2,073 | 2,382 | 3,038 | 3,597 | 3,648 | 3,534 | 3,835 |
| Operating Profit | 159 | 210 | 276 | 299 | 278 | 384 | 526 | 856 | 727 | 915 | 858 | 948 | 1,008 |
| OPM % | 15% | 16% | 20% | 21% | 17% | 17% | 20% | 26% | 19% | 20% | 19% | 21% | 21% |
| Other Income | 4 | 3 | 5 | 35 | 27 | 75 | 90 | 26 | 13 | 12 | 2 | 41 | 28 |
| Interest | 20 | 32 | 37 | 32 | 33 | 28 | 27 | 26 | 23 | 56 | 106 | 103 | 104 |
| Depreciation | 30 | 53 | 58 | 72 | 76 | 105 | 137 | 151 | 159 | 184 | 207 | 226 | 261 |
| Profit before tax | 112 | 128 | 186 | 230 | 196 | 326 | 451 | 704 | 558 | 687 | 547 | 660 | 671 |
| Tax % | 33% | 29% | 33% | 28% | 32% | 27% | 26% | 22% | 26% | 25% | 26% | 24% | |
| Net Profit | 75 | 91 | 123 | 165 | 133 | 236 | 335 | 549 | 413 | 517 | 405 | 502 | 513 |
| EPS in Rs | 3.71 | 4.45 | 5.68 | 7.19 | 5.22 | 9.30 | 13.19 | 22.18 | 16.64 | 21.34 | 16.72 | 20.68 | 21.14 |
| Dividend Payout % | 9% | 11% | 11% | 13% | 19% | 11% | 8% | 7% | 9% | 7% | 9% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 21.33% | 35.16% | 34.15% | -19.39% | 77.44% | 41.95% | 63.88% | -24.77% | 25.18% | -21.66% | 23.95% |
| Change in YoY Net Profit Growth (%) | 0.00% | 13.83% | -1.02% | -53.54% | 96.84% | -35.49% | 21.93% | -88.65% | 49.95% | -46.85% | 45.61% |
Granules India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 12% |
| 3 Years: | 6% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| TTM: | -3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 8% |
| 3 Years: | 19% |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 17% |
| 3 Years: | 15% |
| Last Year: | 14% |
Last Updated: September 5, 2025, 5:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:18 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 20 | 22 | 23 | 25 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 24 |
| Reserves | 336 | 411 | 640 | 881 | 1,279 | 1,504 | 1,818 | 2,149 | 2,562 | 2,811 | 3,201 | 3,691 | 3,959 |
| Borrowings | 442 | 482 | 641 | 656 | 978 | 991 | 892 | 849 | 1,106 | 1,136 | 1,315 | 1,455 | 1,807 |
| Other Liabilities | 194 | 289 | 260 | 319 | 388 | 458 | 487 | 690 | 819 | 932 | 957 | 1,051 | 1,154 |
| Total Liabilities | 992 | 1,203 | 1,563 | 1,879 | 2,670 | 2,979 | 3,223 | 3,713 | 4,512 | 4,903 | 5,498 | 6,221 | 6,944 |
| Fixed Assets | 482 | 617 | 560 | 644 | 777 | 944 | 1,204 | 1,332 | 1,541 | 1,911 | 2,096 | 2,426 | 2,816 |
| CWIP | 125 | 62 | 77 | 267 | 515 | 496 | 294 | 239 | 356 | 239 | 272 | 440 | 702 |
| Investments | 0 | 0 | 70 | 108 | 157 | 210 | 19 | 19 | 20 | 21 | 22 | 22 | 1 |
| Other Assets | 385 | 524 | 856 | 859 | 1,222 | 1,328 | 1,706 | 2,123 | 2,594 | 2,732 | 3,109 | 3,333 | 3,425 |
| Total Assets | 992 | 1,203 | 1,563 | 1,879 | 2,670 | 2,979 | 3,223 | 3,713 | 4,512 | 4,903 | 5,498 | 6,221 | 6,944 |
Below is a detailed analysis of the balance sheet data for Granules India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,959.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,691.00 Cr. (Mar 2025) to 3,959.00 Cr., marking an increase of 268.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,807.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,455.00 Cr. (Mar 2025) to 1,807.00 Cr., marking an increase of 352.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,154.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,051.00 Cr. (Mar 2025) to 1,154.00 Cr., marking an increase of 103.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 6,944.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,221.00 Cr. (Mar 2025) to 6,944.00 Cr., marking an increase of 723.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2,816.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,426.00 Cr. (Mar 2025) to 2,816.00 Cr., marking an increase of 390.00 Cr..
- For CWIP, as of Sep 2025, the value is 702.00 Cr.. The value appears strong and on an upward trend. It has increased from 440.00 Cr. (Mar 2025) to 702.00 Cr., marking an increase of 262.00 Cr..
- For Investments, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 22.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 21.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,425.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,333.00 Cr. (Mar 2025) to 3,425.00 Cr., marking an increase of 92.00 Cr..
- For Total Assets, as of Sep 2025, the value is 6,944.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,221.00 Cr. (Mar 2025) to 6,944.00 Cr., marking an increase of 723.00 Cr..
Notably, the Reserves (3,959.00 Cr.) exceed the Borrowings (1,807.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -283.00 | -272.00 | -365.00 | -357.00 | -700.00 | -607.00 | -366.00 | 7.00 | 726.00 | 914.00 | 857.00 | 947.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 37 | 39 | 101 | 108 | 136 | 108 | 93 | 86 | 90 | 77 | 80 | 77 |
| Inventory Days | 99 | 110 | 128 | 145 | 114 | 112 | 125 | 205 | 190 | 182 | 235 | 284 |
| Days Payable | 77 | 92 | 91 | 116 | 112 | 94 | 102 | 142 | 124 | 124 | 135 | 154 |
| Cash Conversion Cycle | 59 | 57 | 138 | 137 | 138 | 126 | 116 | 150 | 156 | 135 | 179 | 207 |
| Working Capital Days | 14 | 6 | 9 | -2 | 42 | 48 | 63 | 62 | 44 | 36 | 35 | 42 |
| ROCE % | 20% | 19% | 20% | 18% | 12% | 15% | 17% | 25% | 17% | 19% | 15% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Value Fund | 2,441,258 | 2.13 | 135.76 | N/A | N/A | N/A |
| Edelweiss Balanced Advantage Fund | 2,209,668 | 0.92 | 122.88 | N/A | N/A | N/A |
| Aditya Birla Sun Life Small Cap Fund | 1,106,670 | 1.22 | 61.54 | N/A | N/A | N/A |
| Tata Aggressive Hybrid Fund | 1,100,000 | 1.47 | 61.17 | N/A | N/A | N/A |
| Aditya Birla Sun Life Multi-Cap Fund | 1,038,748 | 0.85 | 57.76 | N/A | N/A | N/A |
| Tata Mid Cap Fund | 1,000,767 | 1.03 | 55.65 | N/A | N/A | N/A |
| Tata Large Cap Fund | 533,136 | 1.05 | 29.65 | N/A | N/A | N/A |
| Axis Midcap Fund | 508,096 | 0.09 | 28.26 | N/A | N/A | N/A |
| Edelweiss Aggressive Hybrid Fund | 335,000 | 0.55 | 18.63 | N/A | N/A | N/A |
| Aditya Birla Sun Life Dividend Yield Fund | 250,000 | 0.92 | 13.9 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 20.69 | 16.73 | 21.05 | 16.66 | 22.05 |
| Diluted EPS (Rs.) | 20.68 | 16.72 | 21.00 | 16.60 | 21.95 |
| Cash EPS (Rs.) | 29.98 | 25.28 | 28.97 | 23.04 | 28.30 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 153.19 | 133.08 | 117.13 | 104.32 | 87.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 153.19 | 133.08 | 117.13 | 104.32 | 87.75 |
| Revenue From Operations / Share (Rs.) | 184.78 | 185.93 | 186.41 | 151.81 | 130.72 |
| PBDIT / Share (Rs.) | 39.51 | 35.50 | 38.32 | 29.83 | 35.62 |
| PBIT / Share (Rs.) | 30.21 | 26.94 | 30.70 | 23.44 | 29.50 |
| PBT / Share (Rs.) | 27.22 | 22.58 | 28.39 | 22.50 | 28.44 |
| Net Profit / Share (Rs.) | 20.68 | 16.72 | 21.34 | 16.64 | 22.18 |
| NP After MI And SOA / Share (Rs.) | 20.68 | 16.72 | 21.34 | 16.64 | 22.18 |
| PBDIT Margin (%) | 21.37 | 19.09 | 20.55 | 19.65 | 27.24 |
| PBIT Margin (%) | 16.34 | 14.49 | 16.46 | 15.43 | 22.56 |
| PBT Margin (%) | 14.73 | 12.14 | 15.23 | 14.82 | 21.75 |
| Net Profit Margin (%) | 11.19 | 8.99 | 11.44 | 10.96 | 16.97 |
| NP After MI And SOA Margin (%) | 11.19 | 8.99 | 11.44 | 10.96 | 16.97 |
| Return on Networth / Equity (%) | 13.49 | 12.56 | 18.22 | 15.95 | 25.28 |
| Return on Capital Employeed (%) | 17.24 | 18.99 | 24.04 | 20.24 | 28.76 |
| Return On Assets (%) | 8.02 | 7.34 | 10.53 | 9.14 | 14.79 |
| Long Term Debt / Equity (X) | 0.08 | 0.02 | 0.05 | 0.09 | 0.15 |
| Total Debt / Equity (X) | 0.34 | 0.37 | 0.37 | 0.42 | 0.38 |
| Asset Turnover Ratio (%) | 0.76 | 0.86 | 0.87 | 0.80 | 0.90 |
| Current Ratio (X) | 1.56 | 1.40 | 1.42 | 1.53 | 1.70 |
| Quick Ratio (X) | 0.88 | 0.77 | 0.78 | 0.92 | 1.04 |
| Inventory Turnover Ratio (X) | 3.39 | 1.80 | 2.67 | 2.72 | 3.34 |
| Dividend Payout Ratio (NP) (%) | 7.24 | 8.95 | 3.60 | 9.00 | 4.50 |
| Dividend Payout Ratio (CP) (%) | 5.00 | 5.92 | 2.65 | 6.50 | 3.53 |
| Earning Retention Ratio (%) | 92.76 | 91.05 | 96.40 | 91.00 | 95.50 |
| Cash Earning Retention Ratio (%) | 95.00 | 94.08 | 97.35 | 93.50 | 96.47 |
| Interest Coverage Ratio (X) | 9.28 | 8.13 | 16.58 | 31.87 | 33.56 |
| Interest Coverage Ratio (Post Tax) (X) | 5.56 | 4.83 | 10.24 | 18.78 | 21.90 |
| Enterprise Value (Cr.) | 12503.53 | 11257.54 | 7783.15 | 8280.28 | 8079.39 |
| EV / Net Operating Revenue (X) | 2.79 | 2.50 | 1.73 | 2.20 | 2.50 |
| EV / EBITDA (X) | 13.05 | 13.08 | 8.39 | 11.19 | 9.16 |
| MarketCap / Net Operating Revenue (X) | 2.64 | 2.31 | 1.56 | 2.02 | 2.32 |
| Retention Ratios (%) | 92.75 | 91.04 | 96.39 | 90.99 | 95.49 |
| Price / BV (X) | 3.18 | 3.23 | 2.48 | 2.94 | 3.46 |
| Price / Net Operating Revenue (X) | 2.64 | 2.31 | 1.56 | 2.02 | 2.32 |
| EarningsYield | 0.04 | 0.03 | 0.07 | 0.05 | 0.07 |
After reviewing the key financial ratios for Granules India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 20.69. This value is within the healthy range. It has increased from 16.73 (Mar 24) to 20.69, marking an increase of 3.96.
- For Diluted EPS (Rs.), as of Mar 25, the value is 20.68. This value is within the healthy range. It has increased from 16.72 (Mar 24) to 20.68, marking an increase of 3.96.
- For Cash EPS (Rs.), as of Mar 25, the value is 29.98. This value is within the healthy range. It has increased from 25.28 (Mar 24) to 29.98, marking an increase of 4.70.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 153.19. It has increased from 133.08 (Mar 24) to 153.19, marking an increase of 20.11.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 153.19. It has increased from 133.08 (Mar 24) to 153.19, marking an increase of 20.11.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 184.78. It has decreased from 185.93 (Mar 24) to 184.78, marking a decrease of 1.15.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 39.51. This value is within the healthy range. It has increased from 35.50 (Mar 24) to 39.51, marking an increase of 4.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is 30.21. This value is within the healthy range. It has increased from 26.94 (Mar 24) to 30.21, marking an increase of 3.27.
- For PBT / Share (Rs.), as of Mar 25, the value is 27.22. This value is within the healthy range. It has increased from 22.58 (Mar 24) to 27.22, marking an increase of 4.64.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 20.68. This value is within the healthy range. It has increased from 16.72 (Mar 24) to 20.68, marking an increase of 3.96.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 20.68. This value is within the healthy range. It has increased from 16.72 (Mar 24) to 20.68, marking an increase of 3.96.
- For PBDIT Margin (%), as of Mar 25, the value is 21.37. This value is within the healthy range. It has increased from 19.09 (Mar 24) to 21.37, marking an increase of 2.28.
- For PBIT Margin (%), as of Mar 25, the value is 16.34. This value is within the healthy range. It has increased from 14.49 (Mar 24) to 16.34, marking an increase of 1.85.
- For PBT Margin (%), as of Mar 25, the value is 14.73. This value is within the healthy range. It has increased from 12.14 (Mar 24) to 14.73, marking an increase of 2.59.
- For Net Profit Margin (%), as of Mar 25, the value is 11.19. This value exceeds the healthy maximum of 10. It has increased from 8.99 (Mar 24) to 11.19, marking an increase of 2.20.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.19. This value is within the healthy range. It has increased from 8.99 (Mar 24) to 11.19, marking an increase of 2.20.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.49. This value is below the healthy minimum of 15. It has increased from 12.56 (Mar 24) to 13.49, marking an increase of 0.93.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.24. This value is within the healthy range. It has decreased from 18.99 (Mar 24) to 17.24, marking a decrease of 1.75.
- For Return On Assets (%), as of Mar 25, the value is 8.02. This value is within the healthy range. It has increased from 7.34 (Mar 24) to 8.02, marking an increase of 0.68.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has increased from 0.02 (Mar 24) to 0.08, marking an increase of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.34. This value is within the healthy range. It has decreased from 0.37 (Mar 24) to 0.34, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 0.86 (Mar 24) to 0.76, marking a decrease of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 1.56, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 1. It has increased from 0.77 (Mar 24) to 0.88, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.39. This value is below the healthy minimum of 4. It has increased from 1.80 (Mar 24) to 3.39, marking an increase of 1.59.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.24. This value is below the healthy minimum of 20. It has decreased from 8.95 (Mar 24) to 7.24, marking a decrease of 1.71.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.00. This value is below the healthy minimum of 20. It has decreased from 5.92 (Mar 24) to 5.00, marking a decrease of 0.92.
- For Earning Retention Ratio (%), as of Mar 25, the value is 92.76. This value exceeds the healthy maximum of 70. It has increased from 91.05 (Mar 24) to 92.76, marking an increase of 1.71.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 95.00. This value exceeds the healthy maximum of 70. It has increased from 94.08 (Mar 24) to 95.00, marking an increase of 0.92.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 9.28. This value is within the healthy range. It has increased from 8.13 (Mar 24) to 9.28, marking an increase of 1.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.56. This value is within the healthy range. It has increased from 4.83 (Mar 24) to 5.56, marking an increase of 0.73.
- For Enterprise Value (Cr.), as of Mar 25, the value is 12,503.53. It has increased from 11,257.54 (Mar 24) to 12,503.53, marking an increase of 1,245.99.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.79. This value is within the healthy range. It has increased from 2.50 (Mar 24) to 2.79, marking an increase of 0.29.
- For EV / EBITDA (X), as of Mar 25, the value is 13.05. This value is within the healthy range. It has decreased from 13.08 (Mar 24) to 13.05, marking a decrease of 0.03.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.64. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 2.64, marking an increase of 0.33.
- For Retention Ratios (%), as of Mar 25, the value is 92.75. This value exceeds the healthy maximum of 70. It has increased from 91.04 (Mar 24) to 92.75, marking an increase of 1.71.
- For Price / BV (X), as of Mar 25, the value is 3.18. This value exceeds the healthy maximum of 3. It has decreased from 3.23 (Mar 24) to 3.18, marking a decrease of 0.05.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.64. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 2.64, marking an increase of 0.33.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Granules India Ltd:
- Net Profit Margin: 11.19%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.24% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.49% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.56
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.88
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 29.3 (Industry average Stock P/E: 53.49)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.34
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 11.19%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 15th Floor, Granules Tower, Botanical Garden Road, Hyderabad Telangana 500084 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Krishna Prasad Chigurupati | Chairman & Managing Director |
| Dr. K V S Ram Rao | Joint Managing Director & CEO |
| Mr. Harsha Chigurupati | Non Ind.& Exe.Director |
| Mrs. Uma Devi Chigurupati | Non Ind.& Exe.Director |
| Mr. Kolli Basava Sankar Rao | Non Exe.Non Ind.Director |
| Dr. Saumen Chakraborty | Ind. Non-Executive Director |
| Mrs. Sucharita Rao Palepu | Ind. Non-Executive Director |
| Dr. Sethurathnam Ravi | Ind. Non-Executive Director |
| Mr. Arun Sawhney | Ind. Non-Executive Director |
| Mr. Kapil Kumar Mehan | Ind. Non-Executive Director |
| Mrs. Priyanka Chigurupati | Non Ind.& Exe.Director |
| Mr. Rajiv Pritidas Kakodkar | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Granules India Ltd?
Granules India Ltd's intrinsic value (as of 01 January 2026) is ₹535.67 which is 13.18% lower the current market price of ₹617.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹14,973 Cr. market cap, FY2025-2026 high/low of ₹627/412, reserves of ₹3,959 Cr, and liabilities of ₹6,944 Cr.
What is the Market Cap of Granules India Ltd?
The Market Cap of Granules India Ltd is 14,973 Cr..
What is the current Stock Price of Granules India Ltd as on 01 January 2026?
The current stock price of Granules India Ltd as on 01 January 2026 is ₹617.
What is the High / Low of Granules India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Granules India Ltd stocks is ₹627/412.
What is the Stock P/E of Granules India Ltd?
The Stock P/E of Granules India Ltd is 29.3.
What is the Book Value of Granules India Ltd?
The Book Value of Granules India Ltd is 164.
What is the Dividend Yield of Granules India Ltd?
The Dividend Yield of Granules India Ltd is 0.25 %.
What is the ROCE of Granules India Ltd?
The ROCE of Granules India Ltd is 15.1 %.
What is the ROE of Granules India Ltd?
The ROE of Granules India Ltd is 13.9 %.
What is the Face Value of Granules India Ltd?
The Face Value of Granules India Ltd is 1.00.